|
- New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early . . .
Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management Additional data on the efficacy and
- The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
- Recently Published | The New England Journal of Medicine
Explore this issue of The New England Journal of Medicine (Vol 0 No 0)
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight . . .
Semaglutide at a dose of 2 4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2 4 mg has shown promising results in early-phase trials; the efficacy of the
- Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes
Zimislecel is an allogeneic stem cell–derived islet-cell therapy Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed
- Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 . . .
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with
- Medical Education | NEJM
The Journal announces a series focused on new, neglected, and insidious disruptions in clinical care environments affecting patient care and education The series aims to stimulate new ways of
|
|
|